


Figure S1. Representative MSⁿ (*n* = 2, 3) spectra and proposed fragmentation mechanisms of



homosildenafil (A) and dimethylsildenafil (B). The bracketed numbers next to the *m/z* values indicate the charge state of the ions.




Figure S2. Representative MS^n ($n = 2, 3$) spectra and proposed fragmentation mechanisms of thiohomosildenafil (A) and dimethylthiosildenafil (B). The bracketed numbers next to the m/z values indicate the charge state of the ions.




Figure S3. Representative MS^n ($n = 2, 3$) spectra and proposed fragmentation mechanisms of benzyildenafil (A) and carbodenafil (B). The bracketed numbers next to the m/z values indicate the charge state of the ions.




Figure S4. Representative MS^n ($n = 2, 3$) spectra and proposed fragmentation mechanisms of nor-neosildenafil (A) and cyclopentinafil (B). The bracketed numbers next to the m/z values indicate the charge state of the ions.




Figure S5. Representative MS^2 spectra and proposed fragmentation mechanisms of hydroxythiohomosildenafil (A) and hydroxyhomosildenafil (B). The bracketed numbers next to the m/z values indicate the charge state of the ions.




Figure S6. Representative MS^{*n*} (*n* = 2, 3) spectra and proposed fragmentation mechanisms of chlorodenafil (A) and dichlorodenafil (B). The bracketed numbers next to the *m/z* values indicate the charge state of the ions.




Figure S7. Representative MS² spectra and proposed fragmentation mechanisms of hydroxychlorodenafil (A) and nitrodenafil (B). The bracketed numbers next to the *m/z* values indicate the charge state of the ions.




Figure S8. Representative MS^{*n*} (*n* = 2, 3) spectra and proposed fragmentation mechanisms of udenafil (A) and hongdenafil (B). The bracketed numbers next to the *m/z* values indicate the charge state of the ions.




Figure S9. Representative MS² and proposed fragmentation mechanisms of piperidinohongdenafil (A) and demethylhongdenafil (B). The bracketed numbers next to the *m/z* values indicate the charge state of the ions.




Figure S10. Representative MS² spectra and proposed fragmentation mechanisms of hydroxyhongdenafil (A) and oxohongdenafil (B). The bracketed numbers next to the *m/z* values indicate the charge state of the ions.




Figure S11. Representative MS² spectra and proposed fragmentation mechanisms of desolfovardenafil (A) and nor-neovardenafil (B). The bracketed numbers next to the *m/z* values indicate the charge state of the ions.




Figure S12. Representative MS² spectra and proposed fragmentation mechanisms of pseudovardenafil (A) and acetylvaridenafil (B). The bracketed numbers next to the *m/z* values indicate the charge state of the ions.




Figure S13. Representative MS² spectra and proposed fragmentation mechanisms of hydroxyvaridenafil (A) and acetaminotadalafil (B). The bracketed numbers next to the *m/z* values indicate the charge state of the ions.




Figure S14. Representative MS^2 spectra and proposed fragmentation mechanisms of aminotadalafil (A) and demethyltadalafil (B). The bracketed numbers next to the m/z values indicate the charge state of the ions.




Figure S15. Representative MS^{*n*} (*n* = 2, 3) spectra and proposed fragmentation mechanisms of chloropretadafil (A) and N-octyltadafil (B). The bracketed numbers next to the *m/z* values indicate the charge state of the ions.

Table S1. Accurate masses and mass errors for fragment and precursor ions of PDE-5 inhibitors and their analogs.





















Compound	Elemental composition	Measured mass	Theoretical mass	Δm (mDa)	Error (ppm)
Homosildenafil	C ₂₃ H ₃₂ N ₆ O ₄ S ^a	245.1170 ^b	245.1176	-0.6	-2.45
	C ₁₇ H ₂₀ N ₄ O ₂	312.1576	312.1581	-0.5	-1.60
	C ₁₅ H ₁₆ N ₄ O ₂	284.1266	284.1268	-0.2	-0.70
Dimethylsildenafil	C ₂₃ H ₃₂ N ₆ O ₄ S ^a	245.1174 ^b	245.1176	-0.2	-0.82
	C ₁₇ H ₂₀ N ₄ O ₂	312.1558	312.1581	-2.3	-7.37
	C ₁₅ H ₁₆ N ₄ O ₂	284.1243	284.1268	-2.5	-8.80
Thiohomosildenafil	C ₂₃ H ₃₃ N ₆ O ₃ S ₂	253.1053 ^b	253.1061	-0.8	-3.32
	C ₁₇ H ₁₉ N ₄ OS	328.1364	328.1352	1.2	3.66
	C ₁₅ H ₁₅ N ₄ OS	300.1019	300.1039	-2.0	-6.66
	C ₁₄ H ₁₂ N ₃ O ₃	271.0920	271.0951	-3.1	-11.44
Dimethylthiosildenafil	C ₂₃ H ₃₃ N ₆ O ₃ S ₂ ^a	253.1060 ^b	253.1061	-0.1	-0.56
	C ₁₇ H ₁₉ N ₄ OS	328.1336	328.1352	-1.6	-4.88
	C ₁₅ H ₁₅ N ₄ OS	300.1046	300.1039	0.7	2.33
	C ₁₄ H ₁₂ N ₃ O ₃	271.0892	271.0951	-5.9	-21.76
Benzylsildenafil	C ₂₈ H ₃₄ N ₆ O ₄ S ^a	276.1239 ^b	276.1254	-1.5	-5.43
	C ₂₁ H ₂₈ N ₆ O ₄ S	461.1970	461.1966	0.4	0.87
	C ₁₇ H ₂₀ N ₄ O ₄ S	377.1272	377.1278	-0.6	-1.59
	C ₁₇ H ₁₈ N ₄ O ₂	311.1492	311.1503	-1.1	-3.54
	C ₁₅ H ₁₄ N ₄ O ₂	283.1191	283.1190	0.1	0.35
	C ₁₄ H ₁₄ N ₄ O	255.1196	255.1240	-4.4	-17.25
Carbodenafil	C ₂₄ H ₃₂ N ₆ O ₃ ^a	227.1326 ^b	227.1341	-1.5	-6.60
	C ₁₆ H ₁₄ N ₄ O ₃	311.1119	311.1139	-2.0	-6.43
	C ₂₂ H ₂₈ N ₆ O ₃	213.1164 ^b	213.1184	-2.0	-9.38
	C ₂₀ H ₂₃ N ₅ O ₃	191.5971 ^b	191.5973	-0.2	-1.04
	C ₁₆ H ₁₄ N ₄ O ₃	156.0619 ^b	156.0606	1.3	8.33
	C ₁₈ H ₁₉ N ₅ O ₃	177.5830 ^b	177.5817	1.3	7.32
Nor-neosildenafil	C ₂₂ H ₂₉ N ₅ O ₄ S ^a	460.2011	460.2013	-0.2	-0.43
	C ₂₀ H ₂₅ N ₅ O ₄ S	432.1686	432.1700	-1.4	-3.24
	C ₁₇ H ₂₀ N ₄ O ₄ S	377.1267	377.1278	-1.1	-2.92
	C ₁₇ H ₁₈ N ₄ O ₂	311.1487	311.1503	-1.6	-5.14
	C ₁₅ H ₁₄ N ₄ O ₂	283.1180	283.1190	-1.0	-3.53
	C ₁₄ H ₁₄ N ₄ O	255.1226	255.1240	-1.4	-5.49
	C ₂₆ H ₃₆ N ₆ O ₄ S ^a	265.1322 ^b	265.1332	-1.0	-3.77
Cyclopentinafil	C ₂₁ H ₂₈ N ₆ O ₄ S	231.1009 ^b	231.1019	-1.0	-4.33
	C ₂₁ H ₂₈ N ₆ O ₄ S	461.1951	461.1966	-1.5	-3.25
	C ₁₇ H ₂₀ N ₄ O ₂	312.1581	312.1581	0.0	0.00
	C ₁₉ H ₂₄ N ₆ O ₄ S	217.0846 ^b	217.0863	-1.7	-7.83
	C ₁₅ H ₁₆ N ₄ O ₂	284.1225	284.1268	-4.3	-15.13
	C ₂₃ H ₃₂ N ₆ O ₄ S ₂ ^a	261.1011 ^b	261.1036	-2.5	-9.57
Hydroxythiohomosildenafil	C ₁₇ H ₂₀ N ₄ OS	328.1340	328.1352	-1.2	-3.76
	C ₂₁ H ₂₅ N ₆ O ₃ S ₂	238.0813 ^b	238.0827	-1.4	-5.74
	C ₁₅ H ₁₆ N ₄ OS	300.1028	300.1039	-1.1	-3.78
	C ₂₃ H ₃₂ N ₆ O ₅ S ^a	253.1163 ^b	253.1150	1.3	5.14
Hydroxyhomosildenafil	C ₁₇ H ₁₉ N ₄ O ₂	312.1576	312.1581	-0.5	-1.60
	C ₁₅ H ₁₅ N ₄ O ₂	284.1257	284.1268	-1.1	-3.87
	C ₂₁ H ₂₆ N ₆ O ₄ S	230.0933 ^b	230.0941	-0.8	-3.48
	C ₁₉ H ₂₁ N ₄ O ₃ Cl ^a	389.1370	389.1375	-0.5	-1.28
Chlorodenafil	C ₁₇ H ₁₇ N ₄ O ₃ Cl	361.1066	361.1062	0.4	1.11
	C ₁₅ H ₁₆ N ₄ O ₂	285.1339	285.1346	-0.7	-2.45
Dichlorodenafil	C ₁₉ H ₂₀ N ₄ O ₂ Cl ₂ ^a	407.1034	407.1036	-0.2	-0.49
	C ₁₇ H ₁₆ N ₄ O ₂ Cl ₂	379.0719	379.0723	-0.4	-1.08
















Hydroxychlorodenafil	C ₁₉ H ₂₃ N ₄ O ₃ Cl ^a	391.1538	391.1531	0.7	1.79
	C ₁₇ H ₁₉ N ₄ O ₃ Cl	363.1217	363.1218	-0.1	-0.28
	C ₁₆ H ₁₆ N ₄ O ₃	313.1326	313.1295	3.1	9.90
	C ₁₅ H ₁₆ N ₄ O ₂	285.1346	285.1346	0.0	0.00
Nitrodenafil	C ₁₇ H ₁₉ N ₅ O ₄ ^a	358.1506	358.1510	-0.4	-1.12
	C ₁₅ H ₁₅ N ₅ O ₄	330.1189	330.1197	-0.8	-2.42
Udenafil	C ₂₅ H ₃₆ N ₆ O ₄ S ^a	259.1304 ^b	259.1332	-2.8	-10.81
	C ₂₂ H ₃₀ N ₆ O ₄ S	238.1087 ^b	238.1097	-1.0	-4.20
	C ₁₅ H ₁₇ N ₅ O ₄ S	364.1026	364.1074	-4.8	-13.18
	C ₁₅ H ₁₄ N ₄ O ₃	299.1133	299.1139	-0.6	-2.01
	C ₁₅ H ₁₄ N ₄ O ₂	283.1194	283.1190	0.4	1.41
Hongdenafil	C ₂₅ H ₃₄ N ₆ O ₃ ^a	234.1398 ^b	234.1419	-2.1	-8.97
	C ₂₃ H ₃₀ N ₆ O ₃	220.1223 ^b	220.1262	-3.9	-17.72
	C ₂₁ H ₂₆ N ₆ O ₃	206.1049 ^b	206.1106	-5.7	-27.66
	C ₁₇ H ₁₆ N ₄ O ₃	325.1335	325.1295	4.0	12.30
	C ₁₇ H ₁₈ N ₄ O ₂	311.1454	311.1503	-4.9	-15.75
	C ₁₆ H ₁₆ N ₄ O ₂	297.1330	297.1346	-1.6	-5.38
Piperidinohongdenafil	C ₂₄ H ₃₁ N ₅ O ₃ ^a	438.2501	438.2500	0.1	0.23
	C ₁₉ H ₂₀ N ₄ O ₃	353.1601	353.1608	-0.7	-1.98
	C ₁₈ H ₂₀ N ₄ O ₃	341.1592	341.1608	-1.6	-4.69
	C ₁₇ H ₁₆ N ₄ O ₃	325.1293	325.1295	-0.2	-0.62
Demethylhongdenafil	C ₂₄ H ₃₂ N ₆ O ₃ ^a	227.1331 ^b	227.1341	-1.0	-4.40
	C ₂₂ H ₂₈ N ₆ O ₃	213.1165 ^b	213.1184	-1.9	-8.92
	C ₁₇ H ₁₈ N ₄ O ₂	311.1455	311.1503	-4.8	-15.43
	C ₁₆ H ₁₆ N ₄ O ₂	297.1330	297.1346	-1.6	-5.38
	C ₂₂ H ₂₈ N ₆ O ₃	213.1165 ^b	213.1184	-1.9	-8.92
	C ₁₉ H ₂₁ N ₅ O ₃	184.5896	184.5895	0.1	0.54
Hydroxyhongdenafil	C ₂₅ H ₃₄ N ₆ O ₄ ^a	242.1372 ^b	242.1394	-2.2	-9.09
	C ₂₃ H ₃₀ N ₆ O ₄	228.1228 ^b	228.1237	-0.9	-3.95
	C ₂₃ H ₂₈ N ₆ O ₃	219.1171 ^b	219.1184	-1.3	-5.93
	C ₁₇ H ₁₈ N ₄ O ₃	327.1440	327.1452	-1.2	-3.67
	C ₁₇ H ₂₀ N ₄ O ₂	312.1558	312.1581	-2.3	-7.37
	C ₁₅ H ₁₆ N ₄ O ₂	284.1243	284.1268	-2.5	-8.80
Oxohongdenafil	C ₂₅ H ₃₂ N ₆ O ₄ ^a	241.1306 ^b	241.1315	-0.9	-3.73
	C ₂₂ H ₂₇ N ₅ O ₃	205.6100 ^b	205.6130	-3.0	-14.59
	C ₂₁ H ₂₅ N ₅ O ₃	198.6032 ^b	198.6051	-1.9	-9.57
	C ₂₀ H ₂₃ N ₅ O ₃	191.5963 ^b	191.5973	-1.0	-5.22
	C ₁₉ H ₂₁ N ₅ O ₃	184.5892 ^b	184.5895	-0.3	-1.63
Desulfovardenafil	C ₁₇ H ₂₀ N ₄ O ₂ ^a	313.1648	313.1659	-1.1	-3.51
	C ₁₅ H ₁₆ N ₄ O ₂	285.1348	285.1346	0.2	0.70
	C ₈ H ₁₀ N ₂ O	151.0876	151.0866	1.0	6.62
Nor-neovardenafil	C ₁₈ H ₂₀ N ₄ O ₄ ^a	357.1546	357.1557	-1.1	-3.08
	C ₁₆ H ₁₆ N ₄ O ₄	329.1237	329.1244	-0.7	-2.13
	C ₈ H ₁₀ N ₂ O	151.0877	151.0866	1.1	7.28
	C ₁₅ H ₁₆ N ₄ O ₂	285.1339	285.1346	-0.7	-2.45
Pseudovardenafil	C ₂₂ H ₂₉ N ₅ O ₄ S ^a	460.2016	460.2013	0.3	0.65
	C ₂₀ H ₂₅ N ₅ O ₄ S	432.1722	432.1700	2.2	5.09
	C ₁₇ H ₂₀ N ₄ O ₄ S	377.1273	377.1278	-0.5	-1.33
	C ₁₇ H ₂₀ N ₄ O ₂	312.1564	312.1581	-1.7	-5.45
	C ₁₅ H ₁₆ N ₄ O ₂	284.1255	284.1268	-1.3	-4.58
	C ₈ H ₁₀ N ₂ O	151.0870	151.0866	0.4	2.65
Acetylvaridenafil	C ₂₅ H ₃₄ N ₆ O ₃ ^a	234.1407 ^b	234.1419	-1.2	-5.13
	C ₂₃ H ₃₀ N ₆ O ₃	220.1226 ^b	220.1262	-3.6	-16.35
	C ₂₁ H ₂₆ N ₆ O ₃	206.1135 ^b	206.1106	2.9	14.07
	C ₁₉ H ₂₁ N ₅ O ₃	184.5904 ^b	184.5895	0.9	4.88


	C ₁₅ H ₁₆ N ₄ O ₂	284.1256	284.1268	-1.2	-4.14
	C ₁₇ H ₁₆ N ₄ O ₃	325.1332	325.1295	3.7	11.38
	C ₁₆ H ₁₆ N ₄ O ₂	297.1333	297.1346	-1.3	-4.38
	C ₈ H ₁₀ N ₂ O	151.0876	151.0866	1.0	6.62
Hydroxyvardenafil	C ₂₃ H ₃₂ N ₆ O ₅ S ^a	253.1159 ^b	253.1150	0.9	3.56
	C ₁₇ H ₁₉ N ₄ O ₂	312.1575	312.1581	-0.6	-1.92
	C ₁₅ H ₁₅ N ₄ O ₂	284.1265	284.1268	-0.3	-1.06
	C ₂₁ H ₂₆ N ₆ O ₄ S	230.0938 ^b	230.0941	-0.3	-1.30
	C ₈ H ₁₀ N ₂ O	151.0866	151.0866	0.0	0.00
Acetaminotadalafil	C ₂₃ H ₂₀ N ₄ O ₅ ^a	433.1496	433.1506	-1.0	-2.31
	C ₂₁ H ₁₈ N ₄ O ₄	391.1433	391.1401	3.2	8.18
	C ₁₆ H ₁₄ N ₄ O ₃	311.1121	311.1139	-1.8	-5.79
	C ₁₄ H ₁₂ N ₄ O ₂	269.1029	269.1033	-0.4	-1.49
	C ₁₇ H ₁₁ NO ₂	262.0864	262.0863	0.1	0.38
	C ₁₃ H ₉ N ₃ O	224.0781	224.0818	-3.7	-16.51
	C ₁₁ H ₈ N ₂	169.0780	169.0760	2.0	11.83
Aminotadalafil	C ₂₁ H ₁₈ N ₄ O ₄ ^a	391.1399	391.1401	-0.2	-0.51
	C ₁₄ H ₁₂ N ₄ O ₂	269.1017	269.1033	-1.6	-5.95
	C ₁₇ H ₁₁ NO ₂	262.0859	262.0863	-0.4	-1.53
	C ₁₆ H ₁₁ NO ₂	250.0849	250.0863	-1.4	-5.60
	C ₁₁ H ₈ N ₂	169.0771	169.0760	1.1	6.51
	C ₈ H ₆ O ₂	135.0451	135.0441	1.0	7.40
Demethyltadalafil	C ₂₁ H ₁₇ N ₃ O ₄ ^a	376.1287	376.1292	-0.5	-1.33
	C ₁₇ H ₁₁ NO ₂	262.0856	262.0863	-0.7	-2.67
	C ₁₄ H ₁₁ N ₃ O ₂	254.0912	254.0924	-1.2	-4.72
	C ₁₆ H ₉ NO	232.0744	232.0757	-1.3	-5.60
	C ₁₅ H ₉ N	204.0797	204.0808	-1.1	-5.39
	C ₁₁ H ₈ N ₂	169.0751	169.0760	-0.9	-5.32
	C ₈ H ₆ O ₂	135.0449	135.0441	0.8	5.92
Chloropretadalafil	C ₂₂ H ₁₉ N ₂ O ₅ Cl ^a	427.1039	427.1055	-1.6	-3.75
	C ₂₁ H ₁₅ N ₂ O ₄ Cl	395.0788	395.0793	-0.5	-1.27
	C ₂₀ H ₁₆ N ₂ O ₄	349.1168	349.1183	-1.5	-4.30
	C ₂₀ H ₁₅ NO ₄	334.1063	334.1074	-1.1	-3.29
	C ₁₉ H ₁₁ NO ₃	302.0812	302.0812	0.0	0.00
	C ₁₇ H ₁₁ NO ₂	262.0849	262.0863	-1.4	-5.34
N-Octyltadalafil	C ₂₉ H ₃₃ N ₃ O ₄ ^a	488.2540	488.2544	-0.4	-0.82
	C ₂₂ H ₂₇ N ₃ O ₂	366.2170	366.2176	-0.6	-1.64
	C ₁₉ H ₁₁ NO ₃	302.0778	302.0812	-3.4	-11.26
	C ₁₇ H ₁₁ NO ₂	262.0878	262.0863	1.5	5.72
	C ₂₁ H ₂₇ N ₃ O	338.2207	338.2227	-2.0	-5.91
	C ₁₂ H ₈ N ₂ O	197.0710	197.0709	0.1	0.51
	C ₁₁ H ₈ N ₂	169.0770	169.0760	1.0	5.91

^a Precursor ion; ^b Multiple charged protonated ion [M+2H]²⁺.

Table S2. The structures of PDE-5 inhibitors and their analogues.

Backbone of the structure	Name of compound	R ₁	R ₂
	Sildenafil		
	Homosildenafil		
	Hydroxyhomosildenafil		
	Dimethylsildenafil		
	Cyclopentinafil		
	Norneosildenafil		
	Benzylsildenafil		
	Carbodenafil		
	Hondenafil		C ₂ H ₅
	Hydroxyhongdenafil		
	Demethylhongdenafil		
	Piperidinohongdenafil		
	Oxohongdenafil		
	Chlorodenafil		
	Hydroxychlorodenafil		
	Nitrodenafil		
	Dichlorodenafil		
	Udenafil		C ₃ H ₇
	Thiosildenafil		C ₂ H ₅


	Thiohomosildenafil		
	Hydroxythiohomosildenafil		
	Dimethylthiosildenafil		
	Vardenafil		
	Acetylvardenafil		
	Hydroxyvardenafil		C ₂ H ₅
	norneovardenafil		
	Pseudovardenafil		
	Desulfovardenafil	H	
	Tadalafil	CH ₃	
	Aminotadalafil	NH ₂	
	Acetaminotadalafil		
	Demethyltadalafil	H	
	N-octyltadalafil	C ₈ H ₁₇	
			-
	Chloropretadalafil	-	
	Yohimbine	-	-
	Mirodenafil	-	-




Thioquinapiperifil

-

-



Xanthoanthrafil



Phenolphthalein (IS)

-

-

*All analytes contain guanosine like structure as a pharmacophore.